Tenpoint Therapeutics

New Capabilities

Commercializing YUVEZZI in the U.S. and pursuing approvals in the U.K. and China

For 240 years, reading glasses have treated presbyopia—the gradual loss of near vision that affects nearly everyone over 45—unchanged since Benjamin Franklin invented bifocals in 1785. Two billion people worldwide still rely on reading glasses today. On January 29, 2026, the FDA approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), the first dual-agent eye drop for presbyopia. On October 16, 2026, the agency approved a fourth drop, RYZUMVI (phentolamine ophthalmic solution 0.75%) from Viatris, widening the market.

Updated Oct 17